Skip to main content

Genomics and Genetic Research in Houston Shaping the Future of Health Care

Published Oct 17, 2019 by A.J. Mistretta

Medical Research lab

Houston may be synonymous with energy, space exploration and J.J. Watt, but those in the medical and scientific community might equally associate the nation’s fourth largest city with genomic and genetic research, thanks to the Texas Medical Center. As the world’s largest medical center, it has given rise to Houston as a center of discoveries helping to shape the future of medicine. 

“As people are seeing in their doctors’ offices every day, we are better than ever at predicting, diagnosing, and treating diseases more precisely than ever,” wrote Leslie Biesecker, president of the American Society of Human Genetics, in a recent Houston Chronicle op-ed. “Advances in our understanding of the human genome are giving us crucial insights into how our bodies work and what happens when we get sick.”

Discoveries in Houston help power the global scientific and technology research communities, offering medical progress for patients around the world and help drive the local economy, Biesecker said. It’s one reason her organization brought 9,000 genetic researchers from 80 different countries to Houston in late 2019 for the world’s largest annual conference of the human genomics and genetic research community.

Houston is already home to researchers at Baylor College of Medicine, Texas A&M University Health Science Center, the University of Texas Health Science Center and the University of Texas MD Anderson Cancer Center, to name just a few of the major institutions. Soon, the Texas Medical Center will join with these institutions to begin work on TMC3, a 30-acre biomedical research campus that will ensure Houston continues to lead on life sciences innovation. 

The study of genomics and genetic research is critical to advancing medical treatment for a host of diseases and illnesses. For example, Biesecker points to work currently underway to build databases of genetic cancer markets.

“Genetic sequencing of cancer tumors is helping not only to more accurately diagnose cancers but also to understand what causes them and what drugs could be used to target them, while efforts to understand family history and risk of cancers allow earlier detection," wrote Biesecker.

Researchers are also examining the genetic keystones of diseases such as cardiovascular disease, autism and dementia.

“To be sure, we have along way to go to realize the benefits of genetic and genomic research for people everywhere,” Biesecker wrote. “Yet approaches are driving novel discoveries across the spectrum of biomedical research and yielding life-changing discoveries.”

Learn more about Houston’s robust biotech and life sciences industry and upcoming events related to the sector. Read Biesecker's full op-ed
 

Related News

Health Care

University of Houston, Baylor College of Medicine to Launch Cutting-Edge Research Hub

8/26/24
The University of Houston (UH) and Baylor College of Medicine (BCM) have been awarded a $44.2 million grant from the National Center for Advancing Translational Research. This funding will support the establishment of a regional hub dedicated to advancing clinical and translational research.  Dubbed the Consortium for Translational and Precision Health (CTPH), the new hub will enhance collaboration between the two institutions and other clinical and research groups within the Texas Medical Center. The CTPH aims to expedite the translation of new technologies and discoveries into patient care and real-world impact, provide funding and resources to accelerate pilot projects and research initiatives and connect investigators with local healthcare organizations and government agencies that are dedicated to healthcare, clinical research and policy.  “Research is the engine empowering health care’s life-changing advancements,” said UH President Renu Khator, in a release. “This innovative hub will be a catalyst for groundbreaking discoveries and treatments that improve people’s quality of life. That’s what drives us at UH and we’re ecstatic to cofound a regional hub for change alongside Baylor.”  The hub will be led by BCM’s Christopher Amos, professor and director of the Institute for Clinical and Translational Research, and Dr. Fasiha Kanwal, professor of medicine and chief of the section of gastroenterology and hepatology, alongside UH’s Dr. Bettina M. Beech, clinical professor of population health and chief population health officer.  “The CTPH is a partnership that draws on strengths of both institutions, creating a rich multidisciplinary environment. It will act as the vehicle to enhance the infrastructure and resources needed to effectively conduct research and implement solutions to advance healthcare,” said Dr. Carolyn Smith, interim senior vice president and dean of research at BCM. “It will help implement and create ongoing core research activities that will support the clinical translational science at both institutions.”  This strategic partnership comes at a time when local institutions are intensifying efforts to advance critical research that will deliver vital healthcare solutions. The University of Texas MD Anderson Cancer Center and Rice University recently announced a collaboration to advance fundamental and translational cancer research and develop life-saving technologies. Additionally, a research initiative led by Rice University, in collaboration with MD Anderson, received an $18 million grant to improve tumor removal technology for breast, head and neck cancer.  Learn more about Houston’s Life Sciences industry. 
Read More
Health Care

Houston Methodist to Accelerate Groundbreaking Research with New Lease at Helix Park

1/30/24
Houston Methodist has announced its lease of 75,800 square feet at the Dynamic One building within the thriving ecosystem of TMC Helix Park. The partnership between Houston Methodist, Texas Medical Center and Beacon Capital Partners heralds a new era of collaborative discovery and transformative healthcare solutions.  With Dynamic One serving as the epicenter of modern medicine, Houston Methodist is poised to accelerate its translational research efforts, particularly in cardiovascular sciences, orthopedics and RNA therapeutics.  “We are always focused on translating innovative medical discoveries into viable therapies for patients. These highly entrepreneurial programs, which translate these discoveries to the bedside, are a natural fit within the emerging biotechnology ecosystem that the TMC is cultivating,” said Edward A. Jones, president and CEO, Houston Methodist Research Institute.  Dynamic One's state-of-the-art facilities and collaborative atmosphere provide an ideal setting for Houston Methodist to further its research initiatives and expand its impact within the healthcare community. The inclusion of flexible laboratory space supports Beacon Capital's commitment to focus on the evolving needs of its tenants while fostering a culture of innovation.  With its prime location in the heart of Helix Park, Dynamic One not only provides unparalleled amenities and access but also serves as a hub for community engagement and public events. From its multi-purpose lounge to its expansive outdoor terrace, Dynamic One embodies the spirit of collaboration and discovery that defines TMC Helix Park.  “We are excited to welcome Houston Methodist to this space; their commitment to bench to bedside innovation and track record of transformative new discoveries aligns with our vision for the campus,” said William McKeon, President and CEO, Texas Medical Center. “Beacon Capital has been an outstanding partner in the development of TMC Helix Park, lending their insights to our efforts to design a campus that would seamlessly blend institutions and industry.”  As a cornerstone of the city's healthcare landscape, Houston Methodist's presence within TMC's Helix Park will catalyze innovation, attract top talent and stimulate economic growth.  Learn more about Houston’s life science ecosystem. 
Read More

Related Events

Executive Partners